Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients

• DOI: 10.22034/apjcp.2017.18.4.1007
• Publication Date: 2017-04-01
• Authors: Leszek Miszczyk; A. Namysł-Kaletka; Aleksandra Napier...; Grzegorz Woźniak; Małgorzata Stąpór...; Grzegorz Głowacki; Andrzej Tukiendorf
• Keywords: Cyberknife

Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in treatment low intermediate risk (LR & IR) prostate cancer patients (PCP) provide an evaluation level group impact on results. In addition, androgen deprivation therapy (ADT) usage prostatic specific antigen (PSA) decline after SABR were assessed. Material Methods: A total 400 PCP (213 LR 187 IR, including T2c) irradiated with a CyberKnife using fd 7.25 Gy to TD 36.25 Gy. At start treatment, 60.3% undergoing ADT this gradually decreased 0% 38 months. Follow-up was for median 15.0 Patients monitored completion 1, 4, 8 months later then subsequently every 6 GI (Gastro-Intestinal) GU (Genito-Urinary) acute late adverse effects, PSA evaluated. Results: Failure noted 9 (2.25%) (5 4 IR groups) - relapses 5 nodal metastases. No G3/4 effects (EORTC/RTOG) observed. Some 0.5% G3 0.3% reactions respectively day one month later. The declined 1.5 ng/ml during first 0.6 next three groups results found. An only confirmed time point interactions. Conclusions: is safe effective treatment. inclusion T2c percentage patient failure permit us assumption that procedure could be utilized more advanced cases. do not allow clear definition radioablation IR+